2025-524324-22-00RecruitingPhase 1
A Two-part study to learn the amount of polymyxin E1 in the body over time formed after a single inhaled dose of colistimethate sodium (CMS) in healthy adults (Part 1) and after single inhaled and vein-infused doses of CMS in adults with non‑cystic fibrosis bronchiectasis (NCFB) (Part 2)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 28 Oct 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 55 (estimated)
- First submitted
- 13 May 2026
- Start date
- 2 Nov 2026
- Lead sponsor
- Zambon S.p.A.
- Diseases
- Cystic fibrosis
- EU CT number
- 2025-524324-22-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 55
- 5 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| SGS Belgium | Edegem | Belgium | Recruiting |
| Emmaues | Mechelen | Belgium | Recruiting |
| Multispecialty hospital for active treatment Sveta Sofia EOOD | Sofiya | Bulgaria | Not yet recruiting |
| Centrum Medycyny Oddechowej Mroz sp. j. | Bialystok | Poland | Not yet recruiting |
| Biokinetica S.A. | Jozefow | Poland | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.